Actively Recruiting
Impact of Treating Severe Periodontitis on Inflammatory Activity of Atheromatous Plaques in Patients With Acute Myocardial Infarction (AMI)
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-09-08
210
Participants Needed
1
Research Sites
469 weeks
Total Duration
On this page
Sponsors
A
Assistance Publique - Hôpitaux de Paris
Lead Sponsor
N
National Research Agency, France
Collaborating Sponsor
AI-Summary
What this Trial Is About
Multicenter randomized clinical trial with two arms in patients hospitalized for an AMI nested in the Frenchie registry. Periodontal therapy is performed by periodontists in the intervention group versus treatment by dental surgeons as part of their usual practice in the control group. For the intervention group, periodontal management will be carried out for a maximum of 6 months after randomisation, prolonged by a follow-up of 6 months including a maintenance visit at M9. All patients will have an FDG-PET at M0 and M12 for evaluation of inflammation on carotid atherosclerotic plaques.
CONDITIONS
Official Title
Impact of Treating Severe Periodontitis on Inflammatory Activity of Atheromatous Plaques in Patients With Acute Myocardial Infarction (AMI)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients hospitalized for an acute myocardial infarction and included in the Frenchie registry
- Score �3E�3D 5 on the screening questionnaire for periodontitis
- At least six teeth present (excluding wisdom teeth)
- Signed consent to participate
- Affiliated with French medical insurance (S�e9curit�e9 Sociale)
You will not qualify if you...
- Diseases affecting periodontal status other than cardiovascular or diabetes (e.g., AIDS, rheumatoid arthritis, Chediak-Higashi syndrome, Papillon-Lef�e8vre)
- Systemic antibiotic therapy exceeding 48 hours within 3 months before inclusion
- Acute heart failure
- Uncontrolled ventricular rhythm disorders
- Unable to attend follow-up visits
- Unable to maintain extended position for 20 minutes
- Immunosuppressive therapy longer than 1 month within 6 months before inclusion
- Pregnancy or breastfeeding
- Known allergy to chlorhexidine, povidone, or 18-fluoro-deoxyglucose
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hôpital Bichat, AP-HP
Paris, France
Actively Recruiting
Research Team
P
Philippe Gabriel STEG
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here